Eugenol is neither a long-acting insulin nor a short-acting insulin, but a medium-acting insulin. The generic name of Eugenol is zinc arginine recombinant human insulin, which is a suspension type injection made by adding a certain amount of zinc arginine to short-acting human insulin. Zinc arginine can adsorb insulin to form insoluble particles, which will form a precipitate at the injection site after being injected subcutaneously, and then insulin will be slowly released from the precipitate and absorbed into the blood to prolong the action time. The glucose-lowering effect of zinc concentrate recombinant human insulin starts to take effect 1.5 hours after injection, and the strongest glucose-lowering effect can be maintained for more than 18 hours within 4-12 hours. The onset of action, the time of maximum glucose-lowering effect and the maintenance of glucose-lowering effect of arginine zinc recombinant human insulin are longer than short-acting human insulin and shorter than long-acting human insulin, so it is called medium-acting insulin.